Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | First-in-class anti-CD96 monoclonal antibody alone or with dostarlimab for advanced tumors

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, updates us on the results of a Phase I trial of the first-in-class anti-CD96 monoclonal antibody, GSK6097608, alone or in combination with dostarlimab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors (NCT04446351). This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.